

Edgar Filing: IMMUNOGEN INC - Form 8-K

IMMUNOGEN INC
Form 8-K
August 27, 2002

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): AUGUST 27, 2002

IMMUNOGEN, INC.

(Exact name of registrant as specified in its charter)

MASSACHUSETTS

(State or other
jurisdiction of
incorporation)

0-17999

(Commission
File Number)

04-2726691

(IRS Employer
Identification No.)

128 SIDNEY STREET, CAMBRIDGE, MA 02139

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (617) 995-2500

ITEM 5. OTHER EVENTS.

On August 27, 2002, ImmunoGen, Inc. (the "Company") announced that, effective immediately, its Board of Directors has authorized the repurchase of up to 4.1 million shares of the Company's common stock. The repurchases are to be made at the discretion of management and as market conditions warrant. No time limit was set for the completion of the repurchase program.

The press release announcing the common stock repurchase program is filed as an exhibit to this Form 8-K, and is incorporated by reference into this Item 5. The foregoing description of the press release and the transactions contemplated therein is qualified in its entirety by reference to such exhibit.

Edgar Filing: IMMUNOGEN INC - Form 8-K

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits.

99.1 The Company's Press Release dated August 27, 2002.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IMMUNOGEN, INC.

(Registrant)

Date: August 27, 2002

/s/ Gregg D. Beloff

Gregg D. Beloff

Chief Financial Officer and Vice President

EXHIBIT INDEX

EXHIBIT
NUMBER

DESCRIPTION

99.1

The Company's Press Release dated August 27, 2002.